OT Cybersecurity in Pharma: Protecting Manufacturing Lines and Proprietary Formulas

Pharmaceutical manufacturing sits at the intersection of two high-value targets: the critical manufacturing infrastructure that produces essential medicines, and the proprietary formulations, process parameters, and analytical methods that represent decades of research and development investment. A cyberattack on a pharmaceutical plant is not only an operational disruption - it is potentially an intellectual property theft, a product quality incident, and in the most severe cases a public health event.

The OT environment in a pharmaceutical manufacturing facility is shaped by a regulatory framework that has no equivalent in other industrial sectors: FDA validation requirements, 21 CFR Part 11 electronic records obligations, GMP documentation requirements, and increasingly stringent supply chain security expectations from regulators and large pharmaceutical customers. Security in pharma OT does not operate independently of compliance - it operates within it, and in many cases must satisfy both the GMP inspector and the cybersecurity assessor simultaneously.

This post explains the specific threats facing pharmaceutical OT environments, the security architecture appropriate for pharma manufacturing, and how OT security controls align with the regulatory requirements that define how pharma OT must be operated.

 

The pharmaceutical sector experienced a 68% increase in ransomware attacks targeting OT and IT environments in 2023-2024 Manufacturing disruption was the primary objective in the majority of confirmed incidents - ransomware operators specifically targeted batch manufacturing systems and laboratory information management systems where operational disruption creates time-sensitive pressure due to product expiry, supply chain obligations, and regulatory reporting requirements. Source: Claroty Global State of CPS Security Report, 2024

 

1. The Pharmaceutical OT Environment: What Is at Risk

Pharmaceutical manufacturing OT covers a broader range of systems than most industrial sectors because it spans both the production process and the analytical and documentation systems that GMP compliance requires.

 

OT System	Function in Pharma Manufacturing	Cyber Risk Specific to Pharma
Batch management systems (BMS)	Controls and documents batch manufacturing processes for pharmaceutical products	Manipulation of batch records; introduction of unauthorized process deviations; ransomware targeting batch documentation
DCS and SCADA	Process control for continuous manufacturing - API synthesis, fermentation, formulation	Process manipulation affecting product quality; unauthorized recipe modifications; safety system interference
Laboratory Information Management Systems (LIMS)	Manages analytical testing data, batch release decisions, and quality control records	Data integrity attacks on QC records; manipulation of release decisions; IP theft of analytical methods
Building Management Systems (BMS)	Controls cleanroom HVAC, environmental monitoring, and contamination prevention systems	Environmental manipulation affecting product sterility; contamination events through HVAC system manipulation
Manufacturing Execution Systems (MES)	Tracks materials, equipment, and process steps; generates electronic batch records	Ransomware targeting batch records; unauthorized material substitution; process deviation concealment
Cold chain monitoring systems	Monitors temperature and humidity for temperature-sensitive biologics and vaccines	Manipulation of temperature records; false environmental data concealing product compromise

 

1.1 Proprietary Formulation Data as a High-Value Target

Beyond operational disruption, pharmaceutical OT environments contain proprietary data that represents extraordinary economic value. Drug formulations, process parameters for API synthesis, fermentation recipes for biologics, analytical testing methods, and manufacturing scale-up data are the product of billions of dollars in research and clinical development. Nation-state actors with state-sponsored pharmaceutical industries specifically target this data through OT and laboratory system intrusions that are designed to be invisible rather than disruptive.

The attack pattern for pharmaceutical IP theft does not resemble ransomware: there is no ransom demand, no operational disruption, and no obvious indicator of compromise. The adversary accesses laboratory data systems, batch management systems, and formulation databases, exfiltrates the target data over time, and leaves without triggering any visible incident. Detecting this requires behavioral monitoring of data access patterns in OT and laboratory systems - not just perimeter security.

 

2. Regulatory Context: How FDA GMP and 21 CFR Part 11 Shape OT Security

2.1 GMP Requirements That Create OT Security Obligations

FDA Good Manufacturing Practice regulations require that pharmaceutical manufacturers maintain control over their manufacturing processes and ensure the integrity of manufacturing records. Several GMP requirements create direct OT security obligations:

 

• Process validation: Manufacturing processes must operate within validated parameters. Unauthorized changes to process control system setpoints or recipes violate validation requirements and require investigation and revalidation. OT security controls that prevent unauthorized configuration changes - application whitelisting, change management, access controls on process parameter modification - are simultaneously security controls and GMP compliance controls.
• Electronic batch records integrity: Batch records must be accurate, complete, and protected from unauthorized modification. OT systems that generate batch records must have access controls and audit trails that demonstrate record integrity. A ransomware attack that corrupts batch records, or an insider who modifies process data retroactively, creates both a security incident and a GMP compliance event requiring investigation, CAPA, and potentially product recall.
• Equipment qualification: Manufacturing equipment and control systems must be qualified before use. Changes to OT system software - including security patches - may require requalification. This creates the same patching tension that exists in continuous process manufacturing: security updates are necessary, but the qualification process slows their deployment.

2.2 21 CFR Part 11 and Electronic Records

21 CFR Part 11 establishes FDA requirements for electronic records and electronic signatures in regulated pharmaceutical environments. From an OT security perspective, the most relevant Part 11 requirements are: system access controls that limit system access to authorized individuals, audit trails that capture who accessed or modified electronic records and when, and computer system validation that demonstrates the system performs as intended.

These requirements align directly with OT security controls: access management, audit logging, and system integrity monitoring all satisfy Part 11 requirements while also providing security value. Building OT security controls around Part 11 requirements allows pharma OT security programs to serve both compliance and security objectives simultaneously.

 

Regulatory Alignment Opportunity Pharmaceutical OT security and GMP compliance are not competing priorities. The access controls, audit trails, change management processes, and system integrity requirements of GMP and 21 CFR Part 11 are the same controls that OT security requires. Building OT security controls around the GMP and Part 11 framework allows pharmaceutical manufacturers to satisfy both regulatory and security requirements through a single implementation - reducing the compliance burden while improving security posture.

 

3. The Specific Threat Vectors Targeting Pharmaceutical OT

3.1 Ransomware Targeting Batch Management and MES Systems

Ransomware operators specifically target pharmaceutical batch management systems because the operational pressure is acute: a batch in progress when ransomware strikes may represent millions of dollars of work-in-process and cannot be held indefinitely - biologics and cell therapy products have short process windows after which the batch must be completed or discarded. The combination of immediate operational pressure, product value, and supply chain obligations creates extreme payment urgency.

The attack pathway is typically through the IT network - corporate email, a compromised VPN credential, or an unpatched internet-facing service - followed by lateral movement to the manufacturing IT/OT boundary and then to batch management and MES systems. The historian server and the MES database server, both of which sit at the IT/OT boundary, are the primary lateral movement targets.

3.2 Nation-State IP Theft Targeting Formulation Data

State-sponsored threat actors from countries with strategic pharmaceutical development objectives specifically target Western pharmaceutical OT and laboratory systems for formulation data. The targets include mRNA vaccine manufacturing processes, biologic drug synthesis parameters, small molecule API synthesis routes, and analytical testing methods for proprietary drugs. This activity increased significantly during the COVID-19 pandemic period and has not returned to pre-pandemic levels.

3.3 Insider Threats in High-Value Product Manufacturing

Pharmaceutical manufacturing facilities handling high-value products - biologics, oncology drugs, gene therapy - face elevated insider threat risk. Disgruntled employees with access to formulation data or batch management systems have both the access and the knowledge to cause significant harm - either through deliberate product contamination, unauthorized formulation data exfiltration, or sabotage of batch records. Access management controls that enforce least privilege and monitor for anomalous data access are the primary insider threat controls in pharma OT environments.

 

4. OT Security Architecture for Pharmaceutical Manufacturing

4.1 IT/OT Segmentation Aligned with GMP Zone Architecture

Pharmaceutical manufacturing facilities already organize their physical environment into zones for contamination control - cleanrooms, controlled environments, and unclassified areas. The OT security architecture should mirror this physical zone structure. Batch manufacturing systems in Grade A and B cleanroom environments should be in separate security zones from warehouse management systems, corporate IT, and laboratory systems. Each zone boundary requires defined and monitored conduits for the data flows required by GMP - batch record transfers, laboratory results, environmental monitoring data.

4.2 Change Management Integration with GMP Qualification

Every change to a pharmaceutical OT system - including security patches - requires evaluation against the GMP qualification status of the affected system. The OT security program must integrate with the GMP change control process: security patches are evaluated for qualification impact, implemented through the formal change control procedure, and documented in the qualification records of the affected system. This integration prevents the security team from implementing patches that inadvertently invalidate GMP qualifications, and prevents the quality team from deferring security patches beyond the point where the vulnerability risk is acceptable.

4.3 Audit Trail and Access Control Aligned with Part 11

OT systems that generate 21 CFR Part 11-regulated electronic records must have access controls that limit modification capability to authorized personnel, and audit trails that capture every access and modification event with user identity and timestamp. These controls satisfy both Part 11 requirements and OT security access governance requirements. The audit trail from a Part 11-compliant batch management system is simultaneously the forensic record for any security incident investigation involving that system.

 

Bottom Line Pharmaceutical OT security operates within a regulatory framework that, when properly understood, provides the structure for a defensible security program. GMP change control, Part 11 access management, and batch record integrity requirements create security controls that serve dual purposes. The pharmaceutical manufacturers with the strongest OT security postures are those who recognized this alignment early and built their security program around the regulatory framework rather than in parallel with it.

 

Frequently Asked Questions

Does a security patch require GMP revalidation of the affected OT system?

It depends on the nature of the patch and the validated state of the system. Under GAMP 5 guidance and FDA computer system validation frameworks, changes to validated systems require a change control assessment that evaluates the impact on the validated state. A security patch that modifies operating system components or application code of a validated system may require partial revalidation - typically an impact assessment, regression testing, and updated validation documentation. Minor security configuration changes - firewall rule updates, access control changes, log configuration - typically do not require revalidation but must still go through the formal change control process. The key is having a clear, documented procedure for evaluating the validation impact of security changes, and a defined fast-track process for security patches that have been assessed as not affecting validated functionality.

How does the FDA view cybersecurity in pharmaceutical manufacturing inspections?

FDA has been incorporating cybersecurity into pharmaceutical manufacturing inspections with increasing frequency since 2020. The primary inspection focus is on data integrity - whether electronic records are protected from unauthorized modification - rather than on broader OT security architecture. Inspectors assess whether computer systems used in GMP operations have appropriate access controls, audit trails, and backup procedures. They also assess whether the manufacturer has a computer system validation program that covers changes including security updates. Significant cybersecurity failures that affect data integrity or product quality can result in 483 observations and warning letters. As of 2024, FDA has also issued cybersecurity guidance for medical devices and is expected to extend similar guidance to pharmaceutical manufacturing systems.

What is the difference between a GMP computer system validation and an OT security assessment?

A GMP computer system validation (CSV) verifies that a computer system performs its intended function reliably and that it meets regulatory requirements for data integrity and audit trails. It is a quality assurance process focused on system functionality and regulatory compliance. An OT security assessment evaluates the cybersecurity posture of an OT environment - identifying vulnerabilities, assessing network segmentation, reviewing access controls, and identifying attack pathways. The two exercises address different questions and use different methodologies. However, they share significant overlap in the areas of access control, audit logging, and change management - and conducting them in coordination rather than independently reduces duplication and produces a more complete picture of both the quality and security posture of the OT environment.